ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results
ImmunoGen reported a strong performance for Q3 2020, achieving revenues of $18.2 million, up from $13.3 million year-over-year. The company experienced increased operating expenses of $34.9 million, primarily due to higher R&D costs. Notably, ImmunoGen secured a $40 million upfront payment from Huadong Medicine to develop mirvetuximab in Greater China, with potential milestone payments of $265 million. The net loss for the quarter was $22.4 million, or $0.13 per share. The company maintains a strong cash position of $188.2 million and has updated its 2020 revenue guidance to $60-$65 million.
- Revenue increased to $18.2 million, a 37% year-over-year rise.
- Secured $40 million upfront from Huadong Medicine with potential $265 million in milestones.
- $188.2 million in cash and equivalents as of September 30, 2020.
- Positive clinical trial data presented at ESMO for mirvetuximab.
- Operating expenses rose to $34.9 million, primarily due to R&D costs.
- Net loss of $22.4 million, a slight increase from $21.8 million in Q3 2019.
- Cash used in operations increased to $87.2 million for the first nine months of 2020.
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2020.
“We have generated significant momentum over the last several months, achieving a number of important milestones across the business,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. “Our collaboration with Huadong Medicine accelerates access to mirvetuximab for ovarian cancer patients in Greater China with an ideal partner who brings extensive regional and oncology development and commercialization experience and capabilities. Beyond Greater China, we continue to prioritize enrollment in our pivotal trials and remain on track to report top-line data in the third quarter of 2021 for SORAYA and the first half of 2022 for MIRASOL.”
Enyedy continued, “At ESMO in September, we shared final data from our FORWARD II triplet cohort, which demonstrated the encouraging efficacy and favorable tolerability of mirvetuximab in combination with carboplatin and Avastin® in FRα-positive recurrent, platinum-sensitive ovarian cancer. We are working to define the best path to label expansion for our combination regimens to benefit patients in earlier lines of therapy and establish mirvetuximab as the agent of choice to pair with other agents in ovarian cancer. On the regulatory front, we were pleased to receive FDA Breakthrough Therapy designation for IMGN632 in relapsed or refractory BPDCN, confirming the high unmet need for safe and effective therapies for this rare, aggressive cancer. We continue to advance multiple cohorts with IMGN632 and look forward to presenting updated monotherapy BPDCN expansion data in an oral presentation at ASH. Furthermore, we were pleased to enroll the first patient in our Phase 1 trial evaluating IMGC936, our ADAM9-targeting ADC in co-development with MacroGenics. Finally, we have further strengthened our balance sheet via our At-the-Market facility and business development activities and now expect to fund operations into the second half of 2022.”
RECENT PROGRESS
-
Entered into an exclusive collaboration to develop and commercialize mirvetuximab soravtansine in mainland China, Hong Kong, Macau, and Taiwan (Greater China) for an upfront payment of
$40 million , with the potential to receive additional milestone payments of up to$265 million as certain development, regulatory, and commercial objectives are achieved, as well as low double-digit to high teen royalties as a percentage of mirvetuximab commercial sales. Lazard acted as financial advisor and Ropes & Gray LLP acted as legal advisor to ImmunoGen in support of this transaction. - Continued site activation and patient enrollment in the pivotal SORAYA and confirmatory MIRASOL trials.
- Presented mature data from the FORWARD II platinum-sensitive triplet cohort evaluating mirvetuximab in combination with carboplatin and Avastin® (bevacizumab) at the European Society for Medical Oncology (ESMO) Congress.
- Received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for IMGN632 in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Continued to advance multiple cohorts with IMGN632, including monotherapy expansion in BPDCN and minimal residual disease positive (MRD+) acute myeloid leukemia (AML) following frontline induction therapy and combinations with Vidaza® (azacitidine) and Venclexta® (venetoclax) in relapsed or refractory AML patients.
- Enrolled first patient in a Phase 1 trial evaluating IMGC936, a novel ADAM9-targeting ADC being co-developed with MacroGenics, in solid tumors including non-small cell lung, colorectal, pancreatic, gastric, and triple negative breast cancers.
-
Entered into an exclusive license with Viridian Therapeutics, Inc. to develop and commercialize an insulin-like growth factor-1 receptor (IGF-1R) antibody for all non-oncology indications that do not use radiopharmaceuticals in exchange for an upfront payment, with the potential to receive additional development milestone payments of approximately
$50 million and up to$95 million in sales milestone payments plus mid-single-digit royalties on the commercial sales of any resulting product.
ANTICIPATED UPCOMING EVENTS
-
Present updated data from the IMGN632 monotherapy BPDCN expansion cohort in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in December, which will build upon the abstract data recently released showing an overall response rate of
30% in 23 heavily pretreated, relapsed/refractory patients, along with a favorable safety and tolerability profile, without capillary leak syndrome or need for hospitalization for administration. A trial-in-progress poster on the AML monotherapy and combination cohorts will also be presented. - Support initiation of an investigator sponsored, randomized trial comparing mirvetuximab plus carboplatin versus standard platinum-based therapy in recurrent platinum-sensitive ovarian cancer.
FINANCIAL RESULTS
Revenues for the quarter ended September 30, 2020 were
Operating expenses for the third quarter of 2020 were
Net loss for the third quarter of 2020 was
ImmunoGen had
In October 2020, the Company sold 12.9 million shares of its common stock through its At-the-Market (“ATM") facility, generating net proceeds to the Company of approximately
FINANCIAL GUIDANCE
ImmunoGen has updated its financial guidance for 2020 as follows:
-
revenues between
$60 million and$65 million ; -
operating expenses between
$160 million and$165 million ; and -
cash and cash equivalents at December 31, 2020 to be between
$245 million and$250 million .
Revenue guidance does not include any potential impact from the agreement with Huadong Medicine. ImmunoGen expects that its current cash, inclusive of the
CONFERENCE CALL INFORMATION
ImmunoGen will hold a conference call today at 8:00 a.m. ET to discuss these results. To access the live call by phone, dial (877) 621-5803; the conference ID is 9864218. The call may also be accessed through the Investors and Media section of immunogen.com. Following the call, a replay will be available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
Avastin®, Vidaza®, Venclexta®, and Kadcyla® are registered trademarks of their respective owners.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen’s expectations related to: the occurrence, timing, and outcome of potential pre-clinical, clinical, and regulatory events related to ImmunoGen’s product candidates; and the presentation of pre-clinical and clinical data on ImmunoGen’s product candidates. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen’s actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of ImmunoGen’s pre-clinical and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of pre-clinical studies, clinical trials, and regulatory processes; ImmunoGen’s ability to financially support its product programs; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting impact on ImmunoGen’s industry and business; and other factors more fully described in ImmunoGen’s Annual Report on Form 10-K for the year ended December 31, 2019 and other reports filed with the Securities and Exchange Commission.
| IMMUNOGEN, INC. | ||||||||||||||||
| SELECTED FINANCIAL INFORMATION | ||||||||||||||||
| (in thousands, except per share amounts) | ||||||||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
September 30, |
|
December 31, |
||||||||||||||
2020 |
|
2019 |
||||||||||||||
| ASSETS | ||||||||||||||||
| Cash and cash equivalents | $ |
188,217 |
|
$ |
176,225 |
|
||||||||||
| Other assets |
|
59,735 |
|
|
59,037 |
|
||||||||||
| Total assets | $ |
247,952 |
|
$ |
235,262 |
|
||||||||||
| LIABILITIES AND SHAREHOLDERS' DEFICIT | ||||||||||||||||
| Current portion of deferred revenue | $ |
3,985 |
|
$ |
309 |
|
||||||||||
| Other current liabilities |
|
95,836 |
|
|
77,101 |
|
||||||||||
| Long-term portion of deferred revenue |
|
126,541 |
|
|
127,123 |
|
||||||||||
| Other long-term liabilities |
|
64,481 |
|
|
106,850 |
|
||||||||||
| Shareholders' deficit |
|
(42,891 |
) |
|
(76,121 |
) |
||||||||||
| Total liabilities and shareholders' deficit | $ |
247,952 |
|
$ |
235,262 |
|
||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
Three Months Ended |
|
Nine Months Ended |
||||||||||||||
September 30, |
|
September 30, |
||||||||||||||
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||||
| Revenues: | ||||||||||||||||
| Non-cash royalty revenue | $ |
18,087 |
|
$ |
13,202 |
|
$ |
45,159 |
|
$ |
32,102 |
|
||||
| License and milestone fees |
|
97 |
|
|
79 |
|
|
1,325 |
|
|
5,237 |
|
||||
| Research and development support |
|
5 |
|
|
- |
|
|
17 |
|
|
68 |
|
||||
| Total revenues |
|
18,189 |
|
|
13,281 |
|
|
46,501 |
|
|
37,407 |
|
||||
| Expenses: | ||||||||||||||||
| Research and development |
|
24,685 |
|
|
21,015 |
|
|
75,014 |
|
|
88,467 |
|
||||
| General and administrative |
|
10,231 |
|
|
9,208 |
|
|
28,862 |
|
|
28,686 |
|
||||
| Restructuring charge |
|
- |
|
|
1,020 |
|
|
1,524 |
|
|
20,921 |
|
||||
| Total operating expenses |
|
34,916 |
|
|
31,243 |
|
|
105,400 |
|
|
138,074 |
|
||||
| Loss from operations |
|
(16,727 |
) |
|
(17,962 |
) |
|
(58,899 |
) |
|
(100,667 |
) |
||||
| Non-cash interest expense on liability related to sale of future royalty & convertible bonds |
|
(5,645 |
) |
|
(4,275 |
) |
|
(17,428 |
) |
|
(11,525 |
) |
||||
| Interest expense on convertible bonds |
|
(24 |
) |
|
(24 |
) |
|
(71 |
) |
|
(71 |
) |
||||
| Other income, net |
|
22 |
|
|
511 |
|
|
638 |
|
|
3,316 |
|
||||
| Net loss | $ |
(22,374 |
) |
$ |
(21,750 |
) |
$ |
(75,760 |
) |
$ |
(108,947 |
) |
||||
| Basic and diluted net loss per common share | $ |
(0.13 |
) |
$ |
(0.15 |
) |
$ |
(0.44 |
) |
$ |
(0.74 |
) |
||||
| Basic and diluted weighted average common shares outstanding |
|
174,508 |
|
|
148,479 |
|
|
172,215 |
|
|
148,143 |
|
||||
